Exploring Alternative Funding Opportnities for Dilution Limitation, Accelerated Commercial Transactions & Value Creation

06 Sep 2023
15:30

15:30pm Chair Introduction

To be Confirmed

 

15:35pm Presentation: Title to be Confirmed

  • Bulletpoint 1
  • Bulletpoint 2
  • Bulletpoint 3

Sven Kili, Chief Executive Officer, Antion Biosciences 

 

15:50pm Presentation: Title to be Confirmed

  • Bulletpoint 1
  • Bulletpoint 2
  • Bulletpoint 3

Ayal Ronen, Chief Business Officer, Freemind 

 

16:05 Presentation: Title to be Confirmed

  • Bulletpoint 1
  • Bulletpoint 2
  • Bulletpoint 3

Daniella Kranjac, Founder, Dynamk Capital 

 

16:20pm Presentation: Title to be Confirmed

  • Bulletpoint 1
  • Bulletpoint 2
  • Bulletpoint 3

Presenter to be Confirmed

 

16:35pm Closing Panel with Q&A

With all session participants

Speakers

Sven Kili
Chief Executive Officer
Antion Biosciences
Ayal Ronen
Chief Business Officer
FreeMind Group